Appointment dossier — Serous Carcinomas
Bring this to your appointment. It summarizes what published studies report — it is not medical advice and does not say anything works. Decisions are yours and your care team’s.
Compounds studied in Serous Carcinomas
No studies or cited compounds on file for this cancer yet.
Open recruiting trials (18)
- NCT07115043 · Phase 1 / Phase 2 — A Study to Investigate Safety of AZD6750 in Adult Participants With Select Advanced or Metastatic Solid Tumors (United States)
- NCT06399757 · Phase 1 / Phase 2 — A Study to Investigate APL-5125 in Adults With Advanced Solid Tumors (United States)
- NCT05579366 · Phase 1 / Phase 2 — Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001) (United States)
- NCT05902988 · Phase 1 / Phase 2 — A Phase I/II Study of VLS-1488 in Subjects With Advanced Cancer (United States)
- NCT05150691 · Phase 1 / Phase 2 — A Phase 1/2a Study of DB-1303/BNT323 in Advanced/Metastatic Solid Tumors (United States)
- NCT07503808 · Phase 1 — A Study of IDE034 in Adult Participants With Locally Advanced/Metastatic Solid Tumors Types (United States)
- NCT05005403 · Phase 1 — Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma and Other Solid Tumors, Receiving Intravenous Infusion of Azirkitug Alone or in Combination(s) With Budigalimab, Bevacizumab, or Telisotuzumab Adizutecan (United States)
- NCT06580314 · Phase 3 — Testing Olaparib for One or Two Years, With or Without Bevacizumab, to Treat Ovarian Cancer (United States)
- NCT04111978 · Phase 3 — MAintenance Therapy With Aromatase Inhibitor in Epithelial Ovarian Cancer (MATAO) (Austria)
- NCT04575935 · Phase 3 — Minimally Invasive Surgery After Neoadjuvant Chemotherapy for the Treatment of Stage IIIC-IV Ovarian, Primary Peritoneal, or Fallopian Tube Cancer, LANCE Trial (United States)
- NCT05601700 · Phase 3 — Letrozole for Estrogen/Progesterone Receptor Positive Low-grade Serous Epithelial Ovarian Cancer (LEPRE Trial) (Italy)
- NCT05256225 · Phase 3 — Testing the Addition of Herceptin Hylecta or Phesgo to the Usual Chemotherapy for HER2 Positive Endometrial Serous Carcinoma or Carcinosarcoma (United States)
- NCT07617753 · Phase 1 / Phase 2 — Dual-Targeting CAR-NK Cells for Recurrent Ovarian Cancer (MSLN, FRα, MUC16) pt2 (China)
- NCT05080556 · Phase 2 — Adaptive ChemoTherapy for Ovarian Cancer in Patients With Replased Platinum-sensitive High Grade Serous or High Grade Endometrioid Ovarian Cancer (United Kingdom)
- NCT02491099 · Phase 2 — A Phase II Evaluation of Afatinib in Patients With Persistent or Recurrent HER2-positive Uterine Serous Carcinoma (United States)
- NCT06890338 · Phase 2 — A Study to Assess Anti-Tumor Activity of Intravenously (IV) Infused Carboplatin With Mirvetuximab Soravtansine in Participants With Newly Diagnosed Folate Receptor Alpha (FRα)Expressing Advanced-Stage Serous Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer. (United States)
- NCT05231122 · Phase 2 — Pembrolizumab Combined With Bevacizumab With or Without Agonist Anti-CD40 CDX-1140 for the Treatment of Patients With Recurrent Ovarian Cancer (United States)
- NCT04633239 · Phase 1 — Testing the Addition of Abemaciclib to Olaparib for Women With Recurrent Ovarian Cancer (United States)
Most-relevant first: trials that name Serous Carcinomas, then broader trials you may still qualify for. 65 recruiting trials name this cancer on ClinicalTrials.gov. Eligibility is decided by each trial's team — bring these NCT numbers to your appointment.
Questions to ask your oncologist
- Of the open trials I found (for example NCT07115043), am I eligible for any — here or at a larger cancer center?
- What is my exact diagnosis — the type, subtype, stage, and grade?
- Has my tumor had molecular or genomic testing (e.g. next-generation sequencing), and what did it find?
- Should I have inherited (germline) genetic testing, and could it affect my treatment or my family?
- What is the goal of treatment for me — cure, long-term control, or comfort?
- What are all of my standard treatment options, and what does each one involve?
- What is the realistic benefit of each option, in actual numbers?
- What are the most common and the most serious side effects, and how are they managed?
- How will we know if treatment is working, and how often will I be scanned or tested?
- If the first treatment doesn't work, what are the next options?
- Are there gentler options if I want to prioritize quality of life?
- Am I eligible for any clinical trials — here or at a larger/academic cancer center?
- Is my case reviewed by a multidisciplinary tumor board?
- Would a second opinion at a center that treats my cancer often be worthwhile?
- Could any of my prescriptions, over-the-counter drugs, or supplements interfere with treatment?
- Which symptoms are emergencies, and who do I call after hours?
- Should I see palliative or supportive care alongside my treatment?
- How will treatment affect my daily life, work, and (if it matters to me) fertility?
- What can I safely do myself — diet and activity — and is anything I'm taking risky?
- What will treatment cost, and is financial assistance available?
- Should my tumor tissue be stored (biobanked) for future testing or trials?